How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Central Nervous System Agents Market
- By Therapeutic Class: Antidepressants, Antipsychotics, Anxiolytics, Antiepileptics, Parkinson’s Disease Drugs, Alzheimer’s Disease Drugs
- By Drug Formulation: Oral Tablets, Injectables, Transdermal Patches, Topical Creams, Syrups
- By Mechanism of Action: Selective Serotonin Reuptake Inhibitors (SSRIs), Dopamine Agonists, GABA Modulators, NMDA Receptor Antagonists, Monoamine Oxidase Inhibitors (MAOIs)
- By End-User: Hospitals, Clinics, Home Healthcare Settings, Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Antidepressants leads By Therapeutic Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 282 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.169 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.177 →
Full report · locked preview
Everything inside the Central Nervous System Agents Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Class 6
Drug Formulation 5
Mechanism of Action 5
End-User 4
Companies profiled
Johnson & Johnson
Pfizer Inc.
Roche Holding AG
Novartis AG
Eli Lilly and Company
AbbVie Inc.
Bristol-Myers Squibb Company
Sanofi S.A.
GlaxoSmithKline plc
AstraZeneca plc
Takeda Pharmaceutical Company Limited
Otsuka Holdings Co. Ltd.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bristol-Myers Squibb Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →GlaxoSmithKline plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →AstraZeneca plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Takeda Pharmaceutical Company Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Otsuka Holdings Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Teva Pharmaceutical Industries Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →H. Lundbeck A/S
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sunovion Pharmaceuticals Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,055M by 2033 · 7.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Antidepressants28.7
- Antipsychotics16.0
- Anxiolytics9.5
- Antiepileptics10.8
- Parkinson’s Disease Drugs16.2
- Alzheimer’s Disease Drugs18.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$388.7M → $623.0M · 6.1%
Europe$270.9M → $509.2M · 8.2%
Asia Pacific$247.4M → $413.2M · 6.6%
Latin America$153.1M → $292.3M · 8.4%
Middle East and Africa$117.8M → $228.8M · 8.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.162026
7.172027
7.192028
7.182029
7.202030
7.222031
7.222032
7.242033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Johnson & Johnson20.5
- Pfizer Inc.14.0
- Roche Holding AG7.1
- Novartis AG10.8
- Eli Lilly and Company10.9
- AbbVie Inc.8.6
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Class31.8%
Drug Formulation34.1%
Mechanism of Action16.9%
End-User17.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.1
- Europe24.6
- Asia Pacific20.0
- Latin America14.1
- Middle East and Africa11.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | 91 | 95 | 86 | 91 | 77 | 80 | 87 |
| Pfizer Inc. | 89 | 80 | 89 | 84 | 89 | 86 | 86 |
| Roche Holding AG | 86 | 77 | 81 | 76 | 84 | 66 | 78 |
| Novartis AG | 74 | 72 | 78 | 73 | 77 | 58 | 72 |
| Eli Lilly and Company | 61 | 61 | 56 | 59 | 56 | 56 | 58 |
| AbbVie Inc. | 60 | 63 | 48 | 71 | 63 | 66 | 62 |
| Bristol-Myers Squibb Company | 48 | 43 | 63 | 50 | 65 | 63 | 55 |
| Sanofi S.A. | 43 | 38 | 44 | 55 | 55 | 50 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Johnson & Johnson
- Pfizer Inc.
- Roche Holding AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Johnson & Johnson | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Pfizer Inc. | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Roche Holding AG | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Novartis AG | ✓ | ✓ | ◐ | ◐ | ◐ | − |
| Eli Lilly and Company | − | ✓ | ◐ | ◐ | ◐ | ◐ |
| AbbVie Inc. | ◐ | ◐ | − | ◐ | − | ◐ |
| Bristol-Myers Squibb Company | − | − | ◐ | ◐ | ◐ | ✓ |
| Sanofi S.A. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Johnson & Johnson87
2Pfizer Inc.86
3Roche Holding AG78
4Novartis AG72
5AbbVie Inc.62
6Eli Lilly and Company58
7Bristol-Myers Squibb Company55
8Sanofi S.A.48
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Johnson & JohnsonPfizer Inc.Roche Holding AG
Challenger1
Strong scale, closing on the leaders.
Novartis AG
Contender2
Focused players with pockets of strength.
Eli Lilly and CompanyAbbVie Inc.
Niche2
Specialists in a single segment or region.
Bristol-Myers Squibb CompanySanofi S.A.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Class in North America, then scale across Central Nervous System Agents Market — a $154M beachhead inside a $2.31B market.
Beachhead (SOM)$154Mobtainable near-term
Serviceable (SAM)$900Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Antidepressants
Best fit — highest urgency & budget in Therapeutic Class.
Economic buyer80 fit
Antipsychotics
Strong fit — clear ROI and a fast path to value.
End user65 fit
Anxiolytics
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Formulation & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Mechanism of Action
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel29%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Central Nervous System Agents Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified20%
Evaluation11%
Closed-won6%
$18.7KCAC
$70KLTV
3.8:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Central Nervous System Agents Market is a durable-growth opportunity — $6.28B by 2033, compounding at 6.4%.
TAM · 2025$3.83Btoday
TAM · 2033$6.28Bforecast
CAGR6.4%2027–2033
Cumulative$44.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.28BTotal addressable market
SAM$2.31BServiceable available market
SOM$380MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.4% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Class moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.28BLarge & growingTAM by 2033 at 6.4% CAGR
$2.31BServiceable nowreachable with today’s model
$380MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.90BBear4.2% CAGR
$6.28BBase6.4% CAGR
$8.04BBull8.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Formulation optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Central Nervous System Agents Market — a $3.82B market by 2033. Plan: grow share from 7.6% to 12.6%.
Market size · 2033$3.82Btotal addressable
Market CAGR3.6%2027–2033
Target share12.6%from 7.6% today
Revenue ambition$482Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.6% | 12.6% | Behind |
| Revenue | $304M | $482M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 31.0% | 39.6% | Ahead |
| Customer retention | 87.9% | 92.3% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Formulation capability
A defensible second engine — invest in Drug Formulation to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Formulation
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $49M capacity & capability investment
- Greenlight bolt-on M&A in Drug Formulation
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Central Nervous System Agents Market conversation — a $899M market you can size, segment and defend in minutes.
Market size · 2033$899Mtotal opportunity
Growth9.5%CAGR to 2033
Addressable buyers980+accounts in scope
Typical ROI6.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Class
Goal Grow share in Therapeutic Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.7×return on cost, year one
< 3 mopayback period
$58K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Johnson & JohnsonPfizer Inc.Roche Holding AGNovartis AGEli Lilly and CompanyAbbVie Inc.Bristol-Myers Squibb CompanySanofi S.A.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Central Nervous System Agents Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Central Nervous System Agents Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Central Nervous System Biomarker Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportCentral Oxygen Supply System Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportCentral Station Air Handling Units Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportCentral Storage Units Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportCentral Suction System Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportCentral Tire Inflation Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportCentral Tire Inflation Systems for Agricultural Vehicles Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportCentral Vacuum Cleaner Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportCentral Water Heater Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportCentral Water Purification System Market
Market size, share, segmentation and regional forecast.
$532M market · 2025 base year
View reportCentralised Transformer Equipment Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportCentralized Dust Suction Unit Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.